Side-by-side comparison of AI visibility scores, market position, and capabilities
Practice management platform for 130K independent physicians from Kareo+PatientPop merger; EHR, billing, and patient acquisition marketing for small practices competing with athenahealth.
Tebra (formerly Kareo + PatientPop) is a cloud-based practice management and digital health platform for independent healthcare practices — providing practice management software, electronic health records (EHR), billing and revenue cycle management, patient engagement, and healthcare marketing tools specifically designed for small independent physician practices. Formed through the merger of Kareo (practice management/billing) and PatientPop (healthcare marketing/patient acquisition) in 2022, Tebra serves approximately 130,000 healthcare providers at independent practices across primary care, mental health, dermatology, and specialty care.\n\nTebra's platform addresses the full operational needs of a small medical practice: EHR documentation with templates for common visit types, automated patient appointment reminders and forms, insurance eligibility verification and claims submission, payment collection from patients, and online reputation management (Google reviews, healthcare directory listings). The combined Kareo+PatientPop heritage means Tebra uniquely covers both the clinical and administrative workflow alongside the digital marketing capabilities independent practices need to attract new patients.\n\nIn 2025, Tebra competes in the small practice EHR and practice management market against athenahealth, drchrono, Jane App, and Practice Fusion for independent physician practice software. The independent practice market faces significant headwinds from hospital consolidation — independent physician practices have steadily been acquired into health system employment or affiliated networks, shrinking the addressable market. Tebra's 2025 strategy focuses on the growing behavioral health segment (mental health practices are growing and need modern practice management tools), telehealth integration (virtual visit capability within the EHR workflow), and improving revenue cycle management automation to help practices collect more of what they bill.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.